U.S. Anesthesia Partners settles FTC monopolization charges in Texas

12 articles · Updated · The Wall Street Journal · Apr 24

The FTC announced a confidential settlement with Dallas-based U.S. Anesthesia Partners after alleging a decade-long scheme to dominate the Texas anesthesia market and raise patient costs.
The agreement, which includes no admission of guilt, aims to restore competition in the Texas anesthesia sector. The FTC’s 2023 lawsuit was a high-profile test of antitrust enforcement against private equity-backed healthcare firms.
While charges against private-equity firm Welsh, Carson, Anderson & Stowe were dismissed in 2024, U.S. Anesthesia Partners continued facing scrutiny. The FTC’s approach to private equity has shifted under new leadership, favoring negotiation over litigation.

What market changes must USAP make to 'restore competition' without admitting guilt?

How will the secret USAP settlement actually lower medical bills for Texas patients?

Is the FTC's new task force a bigger threat to healthcare monopolies than past lawsuits?

Does this case signal the end of private equity's 'buy-and-build' strategy in medicine?

With PE linked to rising bankruptcies, can legal settlements alone save struggling hospitals?

Why are investors pouring billions into healthcare despite the increasing regulatory crackdown?